Reducing misclassification bias in cervical dysplasia risk factor analysis with p16-based diagnoses

Journal of Lower Genital Tract Disease

Volumn 18, Issue 3, 2014, Pages 266-272

  Meserve, Emily ^a   Berlin, Michelle ^a   Mori, Tomi ^b   Krum, Robert ^c   Morgan, Terry K ^a  

^a Department of Pathology ^*  (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c KAISER PERMANENTE   (United States)

Author keywords

cervical cancer; epidemiology; misclassification bias; p16 immunohistochemistry

Indexed keywords

EOSIN; HEMATOXYLIN; KI 67 ANTIGEN; PROTEIN P16; P16 PROTEIN, HUMAN; TUMOR PROTEIN;

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER RISK; CONTRACEPTIVE BEHAVIOR; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; EDUCATIONAL STATUS; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; INCOME; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PAPANICOLAOU TEST; PILOT STUDY; PREDICTIVE VALUE; REPRODUCIBILITY; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SINGLE BLIND PROCEDURE; SMOKING; STANDARD; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA; ADOLESCENT; AGED; COHORT ANALYSIS; COMPARATIVE STUDY; EVALUATION STUDY; MIDDLE AGED; PROCEDURES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; UTERINE CERVICAL NEOPLASMS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DIAGNOSTIC ERRORS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM PROTEINS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84903819457     PISSN: 10892591     EISSN: 15260976     Source Type: Journal    
DOI: 10.1097/LGT.0000000000000001     Document Type: Article

References (35)

1. Rosner B, Spiegelman D, Willett WC. Correction of logistic regression relative risk estimates and confidence intervals for random within-person measurement error. Am J Epidemiol 1992;136:1400-13. (Pubitemid 23046425)
2. Bashir SA, Duffy SW. The correction of risk estimates for measurement error. Ann Epidemiol 1997;7:154-64. (Pubitemid 27157066)
3. del Pino M, Garcia S, Futste V, Alonso I, Fuste P, Torne A, et al. Value of p16INK4a as a marker of progression/regression in cervical intraepithelial neoplasia grade 1. Am J Obstet Gynecol 2009;201:488e1-7.
4. GalganoMT, Castle PE, Atkins KA, Brix WK, Nassau SR, Stoler MH. Using biomarkers as objective standards in the diagnosis of cervical biopsies. Am J Surg Pathol 2010;34: 1077-87.
5. Ogino S, Chan AT, Fuchs CS, Giovannucci E. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut 2011;60:397-411.
6. Castle PE, Schiffman M, Wheeler CM, Wentzensen N, Gravitt PE. Impact of improved classification on the association of human papillomavirus with cervical precancer. Am J Epidemiol 2010;171:155-63.
7. Castle PE, Stoler MH, Solomon D, Schiffman M, for the ALTS Group. The relationship of community biopsydiagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses. Am J Clin Pathol 2007;127:805-15.
8. Stoler MH, Schiffman M. Atypical Squamous Cells of Undetermined SignificanceYLow-grade Squamous Intraepithelial Lesion Triage Study (ALTS) Group. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL triage study. JAMA 2001;285:1500-5. (Pubitemid 32221899)
9. American College of Obstetricians and Gynecologists. ACOG committee opinion no. 463: Cervical cancer in adolescents: screening, evaluation, and management. Obstet Gynecol 2010;116(2 Pt 1):469-72.
10. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol 2012;137:516-42.
11. Pinto AP, Schlecht NF, Woo TY, Crum CP, Cibas ES. Biomarker (ProEx C, p16(INK4A), and MiB-1) distinction of high-grade squamous intraepithelial lesion from its mimics. Mod Pathol 2008;21:1067-74.
12. Shi J, Liu H, Wilkerson M, Huang Y, Meschter S, Dupree W, et al. Evaluation of p16INK4a, minichromosome maintenance protein 2, DNA topoisomerase IIalpha, ProEX C, and p16INK4a/ProEX C in cervical squamous intraepithelial lesions. Hum Pathol 2007;38:1335-44. (Pubitemid 47247476)
13. Kruse AJ, Baak JP, de Bruin PC, Jiwa M, Snijders WP, Boodt PJ, et al. Ki-67 immunoquantitation in cervical intraepithelial neoplasia (CIN): a sensitive marker for grading. J Pathol 2001;193:48-54. (Pubitemid 32051112)
14. Saha B, Chaiwun B, Tsao-Wei DD, Groshen SL, Naritoku WY, Atkinson RD, et al. Telomerase and markers of cellular proliferation are associated with the progression of cervical intraepithelial neoplasia lesions. Int J Gynecol Pathol 2007;26:214-22. (Pubitemid 46986052)
15. Badr RE, Walts AE, Chung F, Bose S. BD ProEx C: a sensitive and specific marker of HPV-associated squamous lesions of the cervix. Am J Surg Pathol 2008;32:899-906.
16. Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 1998;153:1741-8. (Pubitemid 28550662)
17. Jabbar SF, Abrams L, Glick A, Lambert PF. Persistence of high-grade cervical dysplasia and cervical cancer requires the continuous expression of the human papillomavirus type 16 E7 oncogene. Cancer Res 2009;69:4407-14.
18. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342-50. (Pubitemid 37328947)
19. Sayed K, Korourian S, Ellison DA, Kozlowski K, Talley L, Horn HV, et al. Diagnosing cervical biopsies in adolescents: the use of p16 immunohistochemistry to improve reliability and reproducibility. J Low Genit Tract Dis 2007;11:141-6. (Pubitemid 47014184)
20. Horn LC, Reichert A, Oster A, Arndal SF, Trunk MJ, Ridder R, et al. Immunostaining for p16INK4a used as a conjunctive tool improves interobserver agreement of the histologic diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol 2008;32:502-12. (Pubitemid 351458292)
21. Klaes R, Benner A, Friedrich T, Ridder R, Herrington S, Jenkins D, et al. p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol 2002;26:1389-99. (Pubitemid 35239415)
22. Kruse AJ, Baak JP, Janssen EA, Bol MG, Kjellevold KH, Fianne B, et al. Low- and high-risk CIN 1 and 2 lesions: prospective predictive value of grade, HPV, and Ki-67 immunoquantitative variables. J Pathol 2003;199:462-70. (Pubitemid 36411223)
23. Keating JT, Cviko A, Riethdorf S, Riethdorf L, Quade BJ, Sun D, et al. Ki-67, cyclin E, and p16INK4 are complimentary surrogate biomarkers for human papillomavirusYrelated cervical neoplasia. Am J Surg Pathol 2001;25:884-91. (Pubitemid 32594981)
24. Agoff SN, Lin P, Morihara J, Mao C, Kiviat NB, Koutsky LA. p16(INK4a) expression correlates with degree of cervical neoplasia: a comparison with Ki-67 expression and detection of high-risk HPV types. Mod Pathol 2003;16:665-73. (Pubitemid 36871499)
25. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74. (Pubitemid 8054849)
26. Belinson S, Smith JS, Myers E, Olshan A, Belinson J, Pretorius R, et al. Descriptive evidence that risk profiles for cervical intraepithelial neoplasia 1, 2, and 3 are unique. Cancer Epidemiol Biomarkers Prev 2008;17:2350-5.
27. Maucort-Boulch D, Plummer M, Castle PE, Demuth F, Safaeian M, Wheeler CM, et al. Predictors of human papillomavirus persistence among women with equivocal or mildly abnormal cytology. Int J Cancer 2010;126:684-91.
28. Schiffman M, Kjaer SK. Chapter 2: natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003;14-9.
29. Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993;85:958-64. (Pubitemid 23177581)
30. Hefler L, Grimm C, Tempfer C, Reinthaller A. Treatment with vaginal progesterone in women with low-grade cervical dysplasia: a phase II trial. Anticancer Res 2010;30: 1257-61.
31. Castellsague X, Munoz N. Chapter 3: cofactors in human papillomavirus carcinogenesisVrole of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr 2003;20-8.
32. Deacon JM, Evans CD, Yule R, Desai M, Binns W, Taylor C, et al. Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN3 among those infected: a case-control study nested within the Manchester cohort. Br J Cancer 2000;83:1565-72.
33. Castle PE,Wacholder S, Lorincz AT, Scott DR, Sherman ME, Glass AG, et al. A prospective study of high-grade cervical neoplasia risk among human papillomavirusYinfected women. J Natl Cancer Inst 2002;94:1406-14. (Pubitemid 35154145)
34. Moreno V, Bosch FX, Munoz N, Meijer CJ, Shah KV, Walboomers JM, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 2002;359:1085-92. (Pubitemid 34270731)
35. Kjellberg L, Hallmans G, Ahren AM, Johansson R, Bergman F, Wadell G, et al. Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection. Br J Cancer 2000;82:1332-8. (Pubitemid 30145354)